- Home
- BRNS vs XGN Comparison
BRNS vs XGN Comparison
Compare BRNS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 253.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRNS | XGN |
|---|---|---|
| Price | $0.72 | $6.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $13.67 |
| AVG Volume (30 Days) | 69.8K | ★ 246.3K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $63,599,000.00 |
| Revenue This Year | N/A | $22.15 |
| Revenue Next Year | N/A | $15.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1766.46 | 14.08 |
| 52 Week Low | $0.64 | $2.67 |
| 52 Week High | $2.92 | $12.23 |
Technical Indicators
Market Signals| Indicator | BRNS | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 24.04 |
| Support Level | $0.68 | $6.37 |
| Resistance Level | $0.78 | $7.29 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 36.38 | 1.63 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.